NFE2L2 and central nervous system cancer: While our work supports a recently described mechanism of ferroptosis modulation by NRF2, it demonstrates, for the first time, the effect in glioblastoma cells: TMZ-resistant glioblastomas cells show higher vulnerability to ferroptosis induction due to high expression of NRF2 and its target ABCC1. Since high MRP1 expression is crucial to eliminating TMZ-resistant glioma cells through ferroptosis induction in vitro, exploiting collateral sensitivity by ferroptosis induction could be the Achilles’ heel to reverse drug resistance in glioblastoma.